On the 24th, Alteogen recorded a double-digit gain, reaffirming its status as a flagship KOSDAQ stock.

According to the Korea Exchange, Alteogen closed at 371,500 won, up 38,500 won from the previous day. The surge reached 11.56%, with the stock climbing as high as 375,500 won during the session, drawing concentrated investor attention.

Buy Orders Spread to Bio Sector Amid Market Rebound

Domestic markets rebounded that day as bargain-hunting buy orders flowed in following the previous day's correction. Both KOSPI and KOSDAQ trended upward, reflecting improved investor sentiment. Retail and institutional investors led the market higher with net buying, while foreign investors were seen taking profits.

Buy orders spread broadly across the biotech sector in particular, placing Alteogen at the center of the upward trend. With growing interest in the global biotech industry recently, expectations for a revaluation of related stocks are also on the rise.

Focus on Platform Technology Competitiveness

Alteogen is a company that has grown based on its antibody and biopharmaceutical platform technology and ranks among the top by market capitalization on the KOSDAQ. Investors are closely watching the company's technological competitiveness, potential for global business expansion, and future R&D outcomes.

Positive trends were also detected on the supply and demand side. Inflows of both institutional funds and retail buy orders supported the stock's rise. Even amid ongoing market volatility, a partial recovery in the preference for growth stocks is interpreted as channeling funds into major biotech stocks.

Outlook and Risks

The securities industry expects that the future global interest rate environment, changes in biotech sector investment sentiment, and key technology development and commercialization milestones will influence the stock's trajectory. However, some analysts note that given the sharp short-term gains, the potential for increased near-term volatility should also be monitored.

[This article was produced with AI assistance. It is based on market forecasts and analyses and does not recommend buying or selling any specific stock. Stock investing carries the risk of principal loss, and all investment decisions and responsibilities lie with the investor.]